Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Health-related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab: Real World Data

NCT06104826 is registered in ClinicalTrials.gov with Newark Beth Israel Medical Center as lead sponsor.

NCT NCT06104826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06104826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Health-related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab: Real World Data
Lead sponsor
Newark Beth Israel Medical Center
Phase
Observational
Overall status
Unknown status
Start date
December 31, 2023
Completion date
December 31, 2025
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a